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Abstract: A method for the analysis of thyroid hormones by liquid chromatography-mass
spectrometry was used for the dissolution testing of single- and dual-component thyroid hormone
supplements via a two-stage biorelevant dissolution procedure. The biorelevant media consisted
of fasted-state simulated gastric fluid and fasted state simulated intestinal fluid at 37 ◦C, and was
investigated using an internationally recognized protocol. The dissolution profiles showed consistent
solubilization for both single- and dual-component batches at pH 6.5 in the fasted-state simulated
intestinal fluid.
Keywords: thyroid; dissolution; liquid chromatography-mass spectrometry
1. Introduction
Thyroid hormones are responsible for the regulation of a variety of metabolic functions, including
basal metabolic rate and lipid, glucose and carbohydrate metabolism [1]. This group of compounds
contains tyrosine-based compounds including the physiologically active form triiodothyronine (T3)
and the prehormone thyroxine (T4). The majority of triiodothyronine is formed enzymatically by the
deiodination of thyroxine [2,3] (Figure 1). Hyperthyroidism and hypothyroidism are the two main
medical conditions associated with thyroid hormone levels. Hypothyroidism is caused by a depleted
level of triiodothyronine, the treatment for which is lifelong thyroid supplement therapy [1,4–7].
Currently, the favoured treatment for hypothyroidism is the administration of levothyroxine sodium
salt, with its cost being a considerable factor [8]. However, a number of studies have found that in
order to maintain euthyroid levels of both T4 and T3, an excess of levothyroxine sodium salt must be
administered [9–11]. This has resulted in products becoming available that contain either T3 alone or a
combination of T4 and T3 in a single dose.
Dissolution testing is widely accepted within the pharmaceutical industry as the measure of
drug release rate to aid in quality control, formulation and process development [12,13]. Noyes and
Whitney, investigating the dissolution of benzoic acid and lead chloride, performed the first reported
study into dissolution in 1897 [14]. However, the importance of dissolution testing for pharmaceutical
quality control and drug formulation was not established until 70 years later [12,15]. Within the
pharmaceutical industry, there are two main categories of dissolution testing performed, biorelevant
and quality control [13]. Biorelevant is an abbreviated term for “biologically relevant”, and the selected
media mimic the fluids found within the stomach (gastric) and intestinal tract [16].
Biorelevant dissolution is a multiple-stage dissolution test designed to model the different in vivo
environments as the dosage passes through the gastrointestinal (GI) tract. A biorelevant dissolution
method is utilized during early formulation selection and optimization but due to the cost and
complexity of the media plus variability of physiological parameters it is replaced by a quality control
dissolution method once formulation has been developed [13,15]. A quality control dissolution method
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consists of one medium that is designed for detecting variations in routine manufacturing or changes
during stability testing (e.g., to detect incorrect granulation or compression [13]).
This paper investigates the bioavailability profile, using simulated in vitro gastrointestinal
extraction media, of thyroid hormone supplements that contain either a single or a dual combination
of the two hormones using biorelevant dissolution media. In addition, the bioavailability profile is
compared against the standard United States Pharmacopoeia (USP) quality control test specification of
70% release within 45 min for individual dosage forms of thyroid hormone supplements [17,18].Separations 2019, 6, x FOR PEER REVIEW 2 of 7 
 
 
Figure 1. Conversion of T4 to T3 by deiodination. 
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2. Materials and Methods
2.1. Chemicals and Reagents
Triiodothyronine and thyroxine/triiodothyronine tablets were purchased from RX Cart (Sagunto,
Valencia, Spain), specifically Cytomel containing 25 µg of T3. Tiromel containing 25 µg of T3 and
Dithyron containing 12.5 µg of T3 and 50 µg of T4 were purchased from http://www.buyt3.co.uk/.
Organic LC–MS grade solvents (methanol, acetonitrile, acetic acid and formic acid) were purchased from
Fisher Scientific (Loughborough, Leicestershire, UK). Standards of T3 and T4 were purchased from Sigma
Aldrich (Poole, Dorset, UK) with a purity of ≥98%. For dissolution media, FaSSIF/FeSSIF/FaSSGF
powder was purchased from Biorelevant (London, UK) and additives (sodium hydroxide pellet and
monobasic sodium phosphate monohydrate) were purchased from Sigma Aldrich (Poole, Dorset)
while sodium chloride, hydrochloric acid and sodiu hydroxide were purchased from Fisher Scientific
(Loughborough, Leicestershire, UK).
2.2. Instrumentation
LC–MS analysis chromatographic separation was achieved on a reversed phase pentafluorophenyl
column (Supelco 2.1 µm F5, 100 × 2.1 mm) from Sigma Aldrich (Poole, Dorset, UK). Thermo
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Surveyor LC (Thermo Scientific, Hemel Hempsted, UK) consisted of a quaternary MS pump, vacuum
degasser, thermostated autosampler (set to 5 ◦C) and a thermostated column oven (set to 25 ◦C).
Mass spectrometry was performed using an LTQ XL ion trap mass spectrometer (Thermo Scientific,
Hemel Hempsted, UK) equipped with a heated electrospray ionization (HESI) source maintained
at 200 ◦C. The solvent evaporation was aided with auxiliary gas, sheath gas and sweep gas set to
an arbitrary flow rate of 15, 60 and 1, respectively. The mass spectrometer was operated in selected
reaction monitoring (SRM) MS/MS in negative mode, with collision energies of 28 eV for T4 and 27 eV
for T3. The monitored transitions were 776→ 604 and 650→ 633 for T4 and T3, respectively. In SRM
MS/MS mode the precursor ion is isolated and subjected to a specified amount of collision energy
to induce fragmentation. The MS method is then set to monitor the precursor and a minimum of
two stable product ions. Sample aliquots of 10 µL were introduced onto the column at a flow rate of
200 µL/min. The analytes were separated using an isocratic method using water +0.2% formic acid
(A) and methanol +0.2% formic acid (B) as the mobile phase.
2.3. Dissolution
Dissolution was carried out using a SOTAX Smart AT7™ dissolution bath from Sotax (Finchley,
London). The dissolution bath was set to 37 ◦C and 250 mL of fasted-state simulated gastric fluid
(FaSSGF) was added to each vessel; the rotor speed set to 75 RPM and allowed to equilibrate for at
least 1 h. The initial and final temperatures and pH were recorded to ensure consistent temperature
and buffer control. Tablet weights were recorded prior to being released into the relevant vessels
simultaneously. Samples were taken at the following time points through probe filters and syringe
filters: 5, 10, 20 and 30 min. The paddles were stopped and 250 mL of fasted-state simulated intestinal
fluid (FaSSIF), added to each vessel and the paddle was resumed. Samples were taken at the following
time points through probe filters and syringe filters: 35, 40, 50, 60, 90, 120, 150, 180, 210 and 240 min.
2.4. Preparation of Stock Solutions and Dissolution Media
Stock solutions of each hormone were prepared at a concentration approximately 0.5 mg/mL in
methanol, aliquoted into 100 µL aliquots and stored at −20 ◦C, as recommended by the manufacturer
to increase the working life of the standard solutions. A fresh working standard solution of both
standards was prepared each week by dilution of stock solutions in mobile phase (70% methanol:
30% water, v/v). Calibration standards were prepared daily for each analysis from the working stock
solution ranging from 1 to 200 ng/mL for LC–MS/MS. A quality control standard containing both
thyroid hormones was also prepared at a concentration of 50 ng/mL.
To prepare the fasted-state small intestinal fluid (FaSSIF) buffer, 0.84 g of sodium hydroxide
pellet, 7.90 g of monobasic sodium phosphate monohydrate and 12.38 g of sodium chloride were
added to approximately 1.8 L of Type 1 water. The solution was pH adjusted to 6.5 with 1 N sodium
hydroxide and made up to 2 L with Type 1 water. To make the final FaSSIF medium, 4.48 g of
FaSSIF/FeSSIF/FaSSGF powder was added to approximately 1 L of FaSSIF buffer. The solution was
stirred until completely dissolved and made up to 2 L with FaSSIF buffer. The solution was allowed to
stand for 2 h prior to use [19]. To prepare the fasted-state gastric fluid (FaSSGF) buffer, 3.2 g of sodium
chloride was added to approximately 1.8 L of Type 1 water. The solution was pH adjusted to 1.6 with
1 N hydrochloric acid and made up to 2 L with Type 1 water. To make the final FaSSGF medium, 0.12 g
of FaSSIF/FeSSIF/FaSSGF powder was added to approximately 1 L of FaSSGF buffer. The solution
was stirred until completely dissolved and made up to 2 L with FaSSGF buffer [19].
2.5. Tablet Analysis
For each batch of tablets, three tablets were weighed and crushed using a pestle and mortar.
In triplicate for each tablet, a fifth of the weight was transferred to a 10 mL volumetric flask, made up
to volume with water, and sonicated for 20 min. The solutions were allowed to cool, then 10 µL was
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transferred to a separate 10 mL volumetric flask and made up to volume with water. The solution was
then filtered through a 0.22 µm nylon filter and placed in autosampler vials for analysis by LC–MS/MS.
3. Results & Discussion
3.1. Tablet Analysis
Calibration data was generated for both T3 and T4 over the concentration range 0–250 ng/mL,
based on 11 data points. Subsequently, the calibration curve obtained gave an r2 value of 0.9962 and
0.9973 for T3 and T4, respectively (Table 1). The developed LC–MS/MS method was both sensitive
and selective for T3 and T4 analysis, with limit of quantitation (LOQ) values of 1.6 and 1.3 ng/mL
and limit of detection (LOD) values of 0.2 and 0.8 ng/mL, respectively. Calculations were based on
the standard curve method: LOD = (3.3σ)/S and LOQ = (10σ)/S, where σ is the standard deviation
and S is the slope of the curve [20]. In addition, a quality control standard (50 ng/mL) was analyzed
throughout the experimental duration and given average recoveries of 99.6% and 102.6% for T3 and
T4, respectively. Tablet analysis was performed prior to dissolution testing to ensure that the stated
dosage was present, as this would be used to indicate 100% of release under dissolution testing. The
tablet analysis was consistent with the dosages stated on the packaging for all four batches of thyroid
supplement with a % content of >93.3% for all batches and replicate preparations (Table 2). Good
inter-batch and inter-tablet precision were also observed with % (relative standard deviation) RSD of
<1.8% and <3.4%, respectively.
Table 1. Analytical data for T3 and T4 by LC–MS/MS.
Compound CalibrationRange (ng/mL)
No of Data
Points Linearity R
2 Value
LOD
(ng/mL)
LOQ
(ng/mL)
T3 0–250 11 Y = 83.622x − 196.97 0.9962 0.2 1.6
T4 0–250 11 Y = 27.338x + 10.442 0.9973 0.8 1.3
LOD = limit of detection; LOQ = limit of quantitation.
Table 2. Tablet analysis: single- and dual-component thyroid hormone supplements.
Single or Dual
Thyroid Hormone
Component
Sample ThyroidHormone Replicate
µg per
Tablet
(n = 3)± SD
% Content
(n = 3)
(%RSD)
% Content per
Batch
(n = 9) (%RSD)
single Cytomel
(batch 1) T3
1 24.4 ± 0.83 97.6 (3.4)
95.6 (1.8)2 23.7 ± 0.27 95.0 (1.2)
3 23.6 ± 0.58 94.3 (2.4)
single Cytomel
(batch 2) T3
1 23.4 ± 0.46 93.6 (2.0)
94.0 (0.8)2 23.7 ± 0.38 94.8 (1.6)
3 23.4 ± 0.51 93.5 (2.2)
single Tiromel T3
1 23.3 ± 0.12 93.3 (0.5)
94.4 (1.3)2 23.9 ± 0.06 95.7 (0.3)
3 23.5 ± 0.19 94.1 (0.8)
dual
Dithyron T3
1 12.4 ± 0.08 99.2 (0.6)
96.3 (2.7)2 11.8 ± 0.13 94.4 (1.1)
3 11.9 ± 0.07 95.2 (0.6)
Dithyron T4
1 49.3 ± 0.21 98.6 (0.4)
98.4 (0.9)2 48.7 ± 0.09 97.4 (0.2)
3 49.6 ± 0.16 99.2 (0.3)
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3.2. Dissolution
In accordance with the United States Pharmacopeia (USP), the tablets are considered to be
dissolved when 75% of the stated dosage has been released [17,18]. The USP method is used as a
quality control method, which is normally deployed to identify variations during manufacturing or
storage stability, and does not mimic the different physiological conditions of the gastrointestinal
tract. The USP-stated method uses alkaline borate buffer (pH 10) and 0.01 N hydrochloric acid
containing 0.2% sodium lauryl sulfate for T3 and T4, respectively, with no proposed method for
dual-component tablets [20]. Therefore, to ensure consistency and allow a direct comparison between
single- and dual-component tablets, biorelevant dissolutions were performed using simulated gastric
and intestinal fluids. The results from the dissolution testing using the simulated gastric and intestinal
fluids of the tablets for the single- and dual-component thyroid hormones are shown in Figure 2. It is
noted that the dissolution for T3 and T4 occurs within approximately 45 min (i.e., 75% dissolution),
which is in agreement with the USP method [17,18]. From Figure 2 it can also be seen that total release
of T3 and T4 from the tablet formulations was obtained within 120 min.
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Figure 2. Dissolution testing profile for T3 and T4 from single- and dual-supplement thyroid
hormone supplements.
The kinetics of dissolution have been investigated using a first-order rate constant (Figure 3).
It was observed that a two-stage dissolution process occurs with crossing points determined by
extrapolation of the line of best fit. The initial rate constant corresponds to tablet coating dissolution
while the second rate constant is indicative of tablet breakdown. The rate constants (k) were calculated
to be between 5.3–6.1 h−1 and 0.4–0.8 h−1 for coating removal and tablet solubilization, respectively.
The rate constant was calculated based on the change in cumulative % drug remaining over time
((y2 − y1)/(x2 − x1)) with y calculated using the equation of the line.
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